🇺🇸 FDA
Pipeline program

Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

SMT112-3003

Phase 3 small_molecule active

Quick answer

Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Metastatic Squamous Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Summit Therapeutics
Indication
Metastatic Squamous Non-small Cell Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials